PD-1/PD-L1抗体阻断药物的研究进展与临床应用 |
| |
引用本文: | 王选年,史烨萍,岳锋.PD-1/PD-L1抗体阻断药物的研究进展与临床应用[J].河南师范大学学报(自然科学版),2021,49(2):87-92. |
| |
作者姓名: | 王选年 史烨萍 岳锋 |
| |
作者单位: | 河南师范大学生命科学学院,河南新乡453007;新乡学院生物技术研究中心,河南新乡453003;河南师范大学生命科学学院,河南新乡453007;新乡学院生物技术研究中心,河南新乡453003 |
| |
摘 要: | 研究发现在生理状况下PD-1与PD-L1相互识别能产生负向信号,该信号通路一旦被激活后,可诱导抗原特异性效应T细胞凋亡,该生理效应可防止过度免疫反应带来的附加损伤,因此该信号通路又被形象的称为“免疫刹车”.如果利用特异性阻断剂阻断PD-1/PD-L1信号通路,便可以恢复免疫细胞的杀伤抑制功能.截止至2019年12月,全...
|
关 键 词: | 抗肿瘤 PD-1/PD-L1 信号通路 临床应用 抗体药物 |
Research progress and clinical application of PD-1/PD-L1 antibody-blocking drugs |
| |
Institution: | ,College of Life Sciences, Henan Normal University,Biotechnology Research Center, Xinxiang University |
| |
Abstract: | Many studies have found that the mutual recognition of PD-1 and PD-L1 could produce negative signals under physiological conditions. Once the signaling pathway was activated, and the signaling pathway could induce the apoptosis of antigen-specific effect T cells. Then the physiological effect could prevent additional damages which caused by excessive immune response. Therefore, the signaling pathway is named as the "immune brake". If the PD-1/PD-L1 signaling pathway was blocked by a specific blocker, the killing inhibitory function of immune cells would be restored. Up to the December of 2019, seven PD-1 blocking drugs and three PD-L1 blocking drugs have been approved for marketing worldwide, all of which belonging to macromolecular antibody drugs. Among them, four PD-1 monoclonal antibodies were independently developed in China. Currently, eight PD-1/PD-L1 blocking drugs have been approved for marketing in mainland China. These monoclonal antibodies have produced good efficacy in the clinical treatment of different tumors. A few patients have achieved complete remission, forecasting a good application prospect for these antibodies. Based on its biological background, we reviewed the application and performance of PD-1/PD-L1 signaling pathway inhibitors in clinical treatment in recent years according to drug classification, and discussed the existing problems in clinical use of such drugs and corresponding strategies. |
| |
Keywords: | anti-tumor PD-1/PD-L1 signal path clinical application antibody drug |
本文献已被 万方数据 等数据库收录! |
|